“R.itemList.length” “- this.config.text.ariaShown
“This.config.text.ariaFermé”
ANN ARBOR, MI / ACCESSWIRE / August 27, 2020 / ENDRA Life Sciences Inc. (‘ENDRA’) (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), exhibits at the Digital International Liver Congress (ILC), organized through the European Association for the Study of the Liver (EASL), 27-29 August 2020.
“Clinical meetings and industry exhibits continue to be a key component of our marketing and logo recognition strategies, and nothing more than EASL,” said Renaud Maloberti, COMMERCIAL Director of ENDRA. “This will be our first virtual convention since the beginning of the global pandemic, and we have responded to this new truth with a virtual stand, which we are very happy to unveil later this week. Our new virtual and interactive stand allows us to be offering EASL participants a memorable delight with our state-of-the-art TAEUS solution and an exclusive arrival to our expert ENDRA team.”
ENDRA’s TAEUS Fatty Liver Imaging (FLIP) imaging system is a convenient, non-invasive way to evaluate liver fats at the point of care. Following the CE mark of TAEUS earlier this year, ENDRA focused on the implementation of key elements of its European marketing plan, adding the status quo of clinical assessment sites that use TAEUS to measure and control liver fats. Simultaneously, ENDRA also submitted a 510 (k) to the U.S. FDA. For THE TAEUS FLIP, which is lately under review.
This year’s “hosted” ILC is giving ENDRA a new opportunity to advertise TAEUS in this important market. The occasion attracts thousands of doctors and scientists in hepatology, gastroenterology, pathology, radiology, images and more from around the world to the network, percentage data, provide effects and talk about the topics and trends around liver disease.
After the convention, the virtual stand of the ENDRA screen will be available in the company or directly in www.endrataeus.com. Hepatologists, gastroenterologists, radiologists and other physicians can get an immersive and very engaging look at TAEUS and enjoy it on their own at their own pace, regardless of convention dates.
About ENDRA Life Sciences Inc. ENDRA Life Sciences Inc. is a pioneer in Thermo Acoustic Enhanced UltraSound (TAEUS®), a revolutionary generation that reflects some MRI-like programs, but at a cost 50 times lower when it comes to patient care. TAEUS is designed to paint in conjunction with one million sonographers in international use. TAEUS, first, focuses on measuring fats in the liver as a means to compare and track NAFLD and NASH, a chronic liver disease that affects more than one billion people internationally and for which there is no practical diagnostic tool. Beyond the liver, ENDRA is exploring several other TAEUS clinical programs, adding visualization of surgical procedures based on tissue temperature energy. www.endrainc.com
Forward-looking statements All statements in this release that are not based on old facts are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. In the future statements, which are based on secure assumptions and describe our long-term plans, methods and expectations, can sometimes be known by using forward-looking terms such as “believe,” “expect,” “may,” “want” “should, “” can “,” seek “,” pretend,” “plan,” “target,” “estimate”, “anticipate”, “or other comparable terms.” Examples of forward-looking statements include, inter alia, time estimates of occasions and long-term achievements, such as expectations previously indexed in “Guidance 2020”; send 510 (k) to the FDA and place the TAEUS device on the market; expectations related to ENDRA’s business strategy. Forward-looking statements involve inherent dangers and insecurities that may cause actual effects to differ materially from those of forward-looking statements, due to a variety of factors, adding our ability to expand commercially viable technology; Receive mandatory regulatory approvals that have a COVID-19 effect on our business plans; our ability to locate and maintain partners of progression, market acceptance of our technology, the quantity and nature of the festival in our industry; Our ability to protect our intellectual assets and other hazards and insecurities described in ENDRA’s filings with the Securities and Exchange Commission. The forward-looking statements made in this press release relate only to the date of this release, and ENDRA assumes no legal responsibility to update such forward-looking statements to reflect actual effects or adjustments to expectations, unless required by law in a different manner.
Company Contact: David Wells CFO (734) [email protected]
Media contact: Denise DiMeglio (610) [email protected]
Investor Relations Contact: Joe Hassett (484) [email protected]
SOURCE: ENDRA Life Sciences Inc.
See the accesswire.com edition: https://www.accesswire.com/603577/ENDRA-Life-Sciences-to-showcase-TAEUSR-Technology-at-EASL-International-Liver-Congress-2020